Although sEH inhibition can improve cardiovascular and renal diseases, the therapeutic potential of sEH inhibition in diet-induced obesity and lipid metabolism disorder is still largely unknown [9]. Here, EPHX2 is linked to obesity due to melanocortin 4 receptor deficiency.